阿格马丁作为阿尔茨海默病的新干预措施:病理洞察力和认知益处
Raj A Katariya1, Shivkumar S Sammeta1, Mayur B Kale1
1Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra 441002, India.
Ageing research reviews
|March 13, 2024
概括
阿格马丁在治疗阿尔茨海默病 (AD) 方面表现有前途,通过准关键的病理过程和增强认知功能. 需要进一步的研究来优化其对阿兹海默症患者的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,没有治愈方法,目前的治疗只能提供症状缓解.
- 现有的治疗方法无法阻止疾病的进展,这凸显了迫切需要新的治疗策略.
- 作为一种自然存在的分子,阿格马丁正在研究其在阿尔茨海默病中潜在的疾病修饰和认知增强作用.
研究的目的:
- 审查目前关于阿格马丁在阿尔茨海默病病理学和认知功能中的作用的证据.
- 探索阿格马丁的作用机制,包括其对粉样β,神经保护和突触可塑性的影响.
- 确定阿格马丁作为潜在的AD治疗方法的挑战和未来研究方向.
主要方法:
- 在阿尔茨海默病的背景下对阿格马丁的临床前和临床研究的审查.
- 对阿格马丁对粉样β的产生,聚合和清除的影响的分析.
- 评估阿格马丁的神经保护性质,神经递质调节,以及对神经发生和突触可塑性的影响.
主要成果:
- 阿格马丁调节关键的阿尔茨海默病过程,包括粉样β代谢.
- 有证据表明,阿格马丁具有神经保护作用并增强认知功能.
- 临床前和临床数据支持agmatine作为AD治疗剂的潜力.
结论:
- 阿格马丁对阿尔茨海默病具有显著的治疗潜力,解决尚未满足的医疗需求.
- 进一步的研究,包括大规模的临床试验和机制研究,对于优化阿格马丁的使用至关重要.
- 阿格马丁可能为阿尔茨海默病的认知增强和疾病修饰提供一种新的方法.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.3K
相关概念视频
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
123
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
123
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
